RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC
STAT
MARCH 7, 2024
A new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first season it was in use. These are the first real-world data showing how effective the product was in the United States.
Let's personalize your content